310436-60-3 Usage
Uses
Used in Pharmaceutical Industry:
Ethyl 5-ethyl-4-hydroxypyridine-2-carboxylate is used as a therapeutic agent for the treatment of osteoporosis, Paget's disease, and other bone disorders. It is utilized for its ability to slow down bone breakdown and increase bone density, which contributes to the prevention of fractures and the management of bone-related conditions.
Used in Bone Health Management:
Ethyl 5-ethyl-4-hydroxypyridine-2-carboxylate serves as a crucial component in bone health management, particularly for individuals suffering from conditions that compromise bone strength and integrity. Its application in this context is aimed at improving bone density and reducing the risk of fractures, thus promoting overall bone health and well-being.
Check Digit Verification of cas no
The CAS Registry Mumber 310436-60-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,0,4,3 and 6 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 310436-60:
(8*3)+(7*1)+(6*0)+(5*4)+(4*3)+(3*6)+(2*6)+(1*0)=93
93 % 10 = 3
So 310436-60-3 is a valid CAS Registry Number.
310436-60-3Relevant academic research and scientific papers
Pyrrolotriazine inhibitors of kinases
-
Page/Page column 62, (2008/06/13)
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
New dual inhibitors of EGFR and HER2 protein tyrosine kinases
Fink, Brian E.,Vite, Gregory D.,Mastalerz, Harold,Kadow, John F.,Kim, Soong-Hoon,Leavitt, Kenneth J.,Du, Karen,Crews, Donald,Mitt, Toomas,Wong, Tai W.,Hunt, John T.,Vyas, Dolatrai M.,Tokarski, John S.
, p. 4774 - 4779 (2007/10/03)
A novel series of dual EGFR and HER2 inhibitors based on the pyrrolo[2,1-f][1,2,4]triazine nucleus is described. A general route toward their synthesis, which enables functionalization at multiple sites, has been developed. Biological evaluation in enzyma
